Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGNNASDAQ:NPCENASDAQ:OBIONASDAQ:SMLR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$9.75-2.9%$13.40$6.59▼$21.00$444.05M1.05477,861 shs559,284 shsNPCENeuroPace$11.07-1.4%$12.87$5.45▼$18.98$363.09M2.03169,089 shs503,404 shsOBIOOrchestra BioMed$3.09-2.2%$2.87$2.37▼$8.87$118.39M0.64170,913 shs154,024 shsSMLRSemler Scientific$29.58-3.8%$35.56$21.77▼$81.56$329.88M1.42509,970 shs649,542 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen-2.89%-10.71%-17.51%-43.48%+20.97%NPCENeuroPace-1.42%-15.82%-29.04%+3.55%+59.28%OBIOOrchestra BioMed-2.22%-6.65%+9.57%-24.26%-61.08%SMLRSemler Scientific-3.77%-10.31%-9.10%-13.89%-27.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXGNAxoGen2.2205 of 5 stars3.52.00.00.01.32.50.6NPCENeuroPace3.7194 of 5 stars3.45.00.00.02.54.20.6OBIOOrchestra BioMed3.0518 of 5 stars4.63.00.00.02.70.80.0SMLRSemler Scientific2.7322 of 5 stars3.52.00.00.01.72.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 3.00Buy$22.20127.69% UpsideNPCENeuroPace 2.83Moderate Buy$15.5040.02% UpsideOBIOOrchestra BioMed 3.20Buy$14.20359.55% UpsideSMLRSemler Scientific 3.00Buy$71.00140.03% UpsideCurrent Analyst Ratings BreakdownLatest OBIO, AXGN, NPCE, and SMLR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025NPCENeuroPaceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.005/14/2025NPCENeuroPaceJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$14.00 ➝ $16.005/14/2025NPCENeuroPaceCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$17.00 ➝ $17.005/13/2025AXGNAxoGenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $24.005/13/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/5/2025OBIOOrchestra BioMedBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $12.004/23/2025OBIOOrchestra BioMedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/22/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/4/2025OBIOOrchestra BioMedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.004/3/2025OBIOOrchestra BioMedB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/1/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$194.52M2.28N/AN/A$2.22 per share4.39NPCENeuroPace$84.31M4.31N/AN/A$0.79 per share14.01OBIOOrchestra BioMed$2.89M41.02N/AN/A$1.90 per share1.63SMLRSemler Scientific$49.23M6.70$1.75 per share16.95$10.45 per share2.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$21.72M-$0.15N/AN/AN/A-7.91%-14.91%-7.49%8/14/2025 (Estimated)NPCENeuroPace-$32.96M-$0.84N/AN/AN/A-36.74%-205.41%-28.29%8/12/2025 (Estimated)OBIOOrchestra BioMed-$49.12M-$1.78N/AN/AN/A-2,179.33%-107.04%-70.88%N/ASMLRSemler Scientific$20.58M-$2.616.02∞N/A72.65%50.77%47.04%8/4/2025 (Estimated)Latest OBIO, AXGN, NPCE, and SMLR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025NPCENeuroPace-$0.26-$0.21+$0.05-$0.21$21.85 million$22.52 million5/13/2025Q1 2025SMLRSemler ScientificN/A-$0.76N/A-$6.74N/A$8.84 million5/12/2025Q1 2025OBIOOrchestra BioMed-$0.46-$0.49-$0.03-$0.49$0.39 million$0.87 million3/31/2025Q4 2024OBIOOrchestra BioMed-$0.43-$0.43N/A-$0.43$0.79 million$0.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/ANPCENeuroPaceN/AN/AN/AN/AN/AOBIOOrchestra BioMedN/AN/AN/AN/AN/ASMLRSemler ScientificN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.673.742.47NPCENeuroPace6.035.594.77OBIOOrchestra BioMedN/A4.234.21SMLRSemler ScientificN/A3.143.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%NPCENeuroPace78.83%OBIOOrchestra BioMed53.55%SMLRSemler Scientific49.37%Insider OwnershipCompanyInsider OwnershipAXGNAxoGen2.78%NPCENeuroPace22.20%OBIOOrchestra BioMed8.10%SMLRSemler Scientific30.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45045.54 million40.93 millionOptionableNPCENeuroPace17032.80 million23.22 millionOptionableOBIOOrchestra BioMed438.31 million35.47 millionNot OptionableSMLRSemler Scientific12011.15 million6.47 millionNot OptionableOBIO, AXGN, NPCE, and SMLR HeadlinesRecent News About These CompaniesBank of America Corp DE Trims Position in Semler Scientific, Inc. (NASDAQ:SMLR)June 14 at 3:10 AM | marketbeat.comSMLR Investor News: If You Have Suffered Losses in Semler Scientific, Inc. (NASDAQ: SMLR), You Are Encouraged to Contact The Rosen Law Firm About Your RightsJune 13 at 5:25 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Semler Scientific Inc. - SMLRJune 13 at 10:15 AM | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Semler Scientific, Inc. (SMLR) And Encourages Shareholders to Reach OutJune 12 at 10:00 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Semler Scientific Inc. - SMLRJune 12 at 9:00 AM | prnewswire.comROSEN, A TOP-RANKED FIRM, Encourages Semler Scientific, Inc. Investors to Inquire About Securities Class Action Investigation - SMLRJune 11 at 9:37 PM | accessnewswire.comTom Lee Mulls Roughed-Up Semler Scientific for 'Granny Shot' PortfolioJune 11 at 4:11 PM | coindesk.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Semler Scientific, Inc. (SMLR) and Encourages Shareholders to Learn More About the InvestigationJune 11 at 10:00 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Semler Scientific Inc. - SMLRJune 11 at 9:00 AM | accessnewswire.comRosen Law Firm Encourages Semler Scientific, Inc. Investors to Inquire About Securities Class Action Investigation - SMLRJune 10, 2025 | prnewswire.comTraders Purchase Large Volume of Semler Scientific Call Options (NASDAQ:SMLR)June 10, 2025 | marketbeat.comSemler Scientific, Inc. (SMLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the InvestigationJune 10, 2025 | accessnewswire.comSMLR Investor News: If You Have Suffered Losses in Semler Scientific, Inc. ...June 9, 2025 | gurufocus.comSMLR Investor News: If You Have Suffered Losses in Semler Scientific, Inc. (NASDAQ: SMLR), You Are Encouraged to Contact The Rosen Law Firm About Your RightsJune 9, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Semler Scientific Inc. - SMLRJune 9, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Encourages Semler Scientific, Inc. (SMLR) Shareholders to Inquire about Securities InvestigationJune 9, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Is Investigating Semler Scientific, Inc. (SMLR) And Encourages Investors to ConnectJune 8, 2025 | accessnewswire.comSMLR Investor News: If You Have Suffered Losses in Semler Scientific, Inc. (NASDAQ: SMLR), You ...June 7, 2025 | bakersfield.comSemler Scientific Inc call volume above normal and directionally bullishJune 7, 2025 | msn.comROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Semler Scientific, Inc. Investors to Inquire About Securities Class Action Investigation - SMLRJune 7, 2025 | markets.businessinsider.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Semler Scientific Inc. - SMLRJune 7, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOBIO, AXGN, NPCE, and SMLR Company DescriptionsAxoGen NASDAQ:AXGN$9.75 -0.29 (-2.89%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$10.01 +0.26 (+2.67%) As of 06/13/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.NeuroPace NASDAQ:NPCE$11.07 -0.16 (-1.42%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$11.10 +0.03 (+0.27%) As of 06/13/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.Orchestra BioMed NASDAQ:OBIO$3.09 -0.07 (-2.22%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.28 +0.19 (+5.99%) As of 06/13/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.Semler Scientific NASDAQ:SMLR$29.58 -1.16 (-3.77%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$29.74 +0.17 (+0.56%) As of 06/13/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
